Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
June 13 2018 - 7:00AM
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company
developing targeted and immuno-oncology therapeutics, today
announced that Christopher K. Mirabelli, Ph.D., Chairman, President
and Chief Executive Officer, will present a corporate overview at
the 2018 JMP Securities Life Sciences Conference, being held in New
York City on June 20-21, 2018.
JMP Securities Life Sciences Conference – Leap Presentation
Details:Date: Wednesday, June 20, 2018Time: 11:30 A.M.
The presentation will be webcast live and may be accessed on the
Investors page of the company’s website at
www.investors.leaptx.com, where a replay of the event will also be
available for a limited time.
About Leap TherapeuticsLeap Therapeutics
(NASDAQ:LPTX) is developing targeted and immuno-oncology
therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a
humanized monoclonal antibody targeting the Dickkopf-1 (DKK1)
protein, a Wnt pathway modulator. DKN-01 is in clinical trials in
patients with esophagogastric cancer, biliary tract cancer, and
gynecologic cancers, with an emerging focus on patients with
defined mutations of the Wnt pathway and in combinations with
immune checkpoint inhibitors. Leap’s second clinical candidate,
TRX518, is a novel, humanized GITR agonist monoclonal antibody
designed to enhance the immune system’s anti-tumor response that is
in two advanced solid tumor studies. For more information
about Leap Therapeutics, visit http://www.leaptx.com or our public
filings with the SEC that are available via EDGAR at
http://www.sec.gov or via http://www.investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements relating to
Leap’s expectations with respect to the development and advancement
of DKN-01, TRX518, and other programs, including the initiation,
timing and design of future studies, enrollment in future studies,
business development, and other future expectations, plans and
prospects. Detailed information regarding factors that may cause
actual results to differ materially will be included in Leap
Therapeutics’ periodic filings with the Securities and
Exchange Commission (the "SEC"), including Leap Therapeutics’
Form 10-K that Leap filed with the SEC on February 23, 2018. Any
forward looking statements contained in this release speak only as
of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
Douglas E. OnsiChief Financial OfficerLeap Therapeutics,
Inc.donsi@leaptx.com617-714-0360
Argot PartnersInvestor RelationsSusan Kim or Heather
Savelle212-600-1902susan@argotpartners.comheather@argotpartners.com
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jul 2023 to Jul 2024